The use of belimumab in three cases of refractory lupus nephritis

Intern Med J. 2023 Oct;53(10):1901-1906. doi: 10.1111/imj.16242.

Abstract

In recent trials for the treatment of systemic lupus erythematosus (SLE), belimumab (BLM), in addition to standard immunosuppression, has been shown to improve renal and nonrenal outcomes. We report our experience using BLM in three cases of refractory lupus nephritis (LN), where renal remission was not achieved using cyclophosphamide, mycophenolate mofetil and other immunosuppressive medications. In two of the three cases, BLM therapy led to a partial remission of LN, improvement in serological markers of SLE and disease activity, which permitted a reduction in prednisolone dosing. Treatment with efficacious therapies early in the course of LN is a desirable therapeutic strategy, to achieve early remission of proteinuria and curtail the development of irreversible chronic renal damage. Further studies are needed to provide information on the effectiveness of BLM for maintenance of remission, prevention of flares and monitoring for long-term complications of B-cell modulation.

Keywords: belimumab; lupus; refractory.

MeSH terms

  • Antibodies, Monoclonal, Humanized / therapeutic use
  • Humans
  • Immunosuppressive Agents / therapeutic use
  • Lupus Erythematosus, Systemic* / complications
  • Lupus Erythematosus, Systemic* / drug therapy
  • Lupus Nephritis* / complications
  • Lupus Nephritis* / drug therapy
  • Treatment Outcome

Substances

  • belimumab
  • Immunosuppressive Agents
  • Antibodies, Monoclonal, Humanized